Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Ketamine for Pediatric Sickle Cell Vasoocclusive Crisis
NCT02573714Unknown
- Sponsor
- Cameroon Baptist Convention Health Services
- Start
- Dec 2015
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised, double-blind trial of ketamine in sickle cell disease (SCD), sponsored by Cameroon Baptist Convention Health Services. Primary endpoint: Faces Pain Scale - Revised. Status: unknown.
02
Drugs
ketamine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02573714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573714.